Mesenteric fat lipolysis mediates obesity-associated hepatic steatosis and insulin resistance

Diabetes

Volumn 65, Issue 1, 2016, Pages 140-148

  Wueest, Stephan ^a   Item, Flurin ^a   Lucchini, Fabrizio C ^a,b   Challa, Tenagne D ^a   Müller, Werner ^c   Blüher, Matthias ^d   Konrad, Daniel ^a,b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLYCOPROTEIN GP 130; INSULIN; INTERLEUKIN 6; MESSENGER RNA; SUPPRESSOR OF CYTOKINE SIGNALING 3; IL6ST PROTEIN, MOUSE;

ADIPOCYTE; ADIPOGENESIS; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SIZE; CONTROLLED STUDY; DISEASE ASSOCIATION; EPIDIDYMIS FAT; FATTY LIVER; FEMALE; GENOTYPE; GLUCOSE INFUSION; GLUCOSE TRANSPORT; HUMAN; HUMAN TISSUE; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID ANALYSIS; LIPID DIET; LIPID LIVER LEVEL; LIPOLYSIS; MAJOR CLINICAL STUDY; MALE; MESENTERIC FAT; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; SYSTEMIC CIRCULATION; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ABDOMINAL FAT; ANIMAL; GENETICS; GLUCOSE CLAMP TECHNIQUE; KNOCKOUT MOUSE; LIVER; METABOLISM; OMENTUM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT; WESTERN BLOTTING;

ABDOMINAL FAT; ADIPOCYTES; ADIPOSE TISSUE, WHITE; ANIMALS; BLOTTING, WESTERN; CYTOKINE RECEPTOR GP130; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; INTERLEUKIN-6; LIPOLYSIS; LIVER; MALE; MICE; MICE, KNOCKOUT; OBESITY; OMENTUM; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBCUTANEOUS FAT;

EID: 84962164178     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0941     Document Type: Article

References (53)

1. Lazo M, Hernaez R, Eberhardt MS, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45
2. Carey AL, Febbraio MA. Interleukin-6 and insulin sensitivity: friend or foe? Diabetologia 2004;47:1135-1142
3. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008;103:1036-1042
4. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007;47:142-156
5. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol 2008;103:1372-1379
6. Ellingsgaard H, Ehses JA, Hammar EB, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008;105:13163-13168
7. Wolf J, Rose-John S, Garbers C. Interleukin-6 and its receptors: a highly regulated and dynamic system. Cytokine 2014;70:11-20
8. Febbraio MA. gp130 receptor ligands as potential therapeutic targets for obesity. J Clin Invest 2007;117:841-849
9. White UA, Stephens JM. The gp130 receptor cytokine family: regulators of adipocyte development and function. Curr Pharm Des 2011;17:340-346
10. Yeoh GC, Ernst M, Rose-John S, et al. Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology 2007;45:486-494
11. Franckhauser S, Elias I, Rotter Sopasakis V, et al. Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 2008;51:1306-1316
12. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 2003;52:2784-2789
13. Wunderlich FT, Ströhle P, Könner AC, et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab 2010;12:237-249
14. van Hall G, Steensberg A, Sacchetti M, et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J Clin Endocrinol Metab 2003;88:3005-3010
15. Wueest S, Item F, Boyle CN, et al. Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. Am J Physiol Regul Integr Comp Physiol 2014;306:R861-R867
16. Perry RJ, Camporez JP, Kursawe R, et al. Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes. Cell 2015; 160:745-758
17. Lam YY, Ha CW, Campbell CR, et al. Increased gut permeability and mi-crobiota change associate with mesenteric fat inflammation and metabolic dysfunction in diet-induced obese mice. PLoS One 2012;7:e34233
18. Li H, Lelliott C, Håkansson P, et al. Intestinal, adipose, and liver inflammation in diet-induced obese mice. Metabolism 2008;57:1704-1710
19. de Guia RM, Rose AJ, Sommerfeld A, et al. microRNA-379 couples glu-cocorticoid hormones to dysfunctional lipid homeostasis. EMBO J 2015;34:344-360
20. Klöting N, Fasshauer M, Dietrich A, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab 2010;299:E506-E515
21. Blüher M, Unger R, Rassoul F, Richter V, Paschke R. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or type II diabetes. Diabetologia 2002;45:210-216
22. Betz UA, Bloch W, van den Broek M, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 1998;188:1955-1965
23. Chin SH, Item F, Wueest S, et al. Opposing effects of reduced kidney mass on liver and skeletal muscle insulin sensitivity in obese mice. Diabetes 2015;64: 1131-1141
24. Fisher SJ, Kahn CR. Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production. J Clin Invest 2003;111: 463-468
25. Kim JK, Michael MD, Previs SF, et al. Redistribution of substrates to adipose tissue promotes obesity in mice with selective insulin resistance in muscle. J Clin Invest 2000;105:1791-1797
26. Wueest S, Yang X, Liu J, Schoenle EJ, Konrad D. Inverse regulation of basal lipolysis in perigonadal and mesenteric fat depots in mice. Am J Physiol Endo-crinol Metab 2012;302:E153-E160
27. Wiedemann MS, Wueest S, Grob A, Item F, Schoenle EJ, Konrad D. Short-term HFD does not alter lipolytic function of adipocytes. Adipocyte 2014;3:115-120
28. Wueest S, Rapold RA, Schumann DM, et al. Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in mice. J Clin Invest 2010;120:191-202
29. Konrad D, Rudich A, Schoenle EJ. Improved glucose tolerance in mice receiving intraperitoneal transplantation of normal fat tissue. Diabetologia 2007; 50:833-839
30. Wueest S, Rapold RA, Rytka JM, Schoenle EJ, Konrad D. Basal lipolysis, not the degree of insulin resistance, differentiates large from small isolated adipo-cytes in high-fat fed mice. Diabetologia 2009;52:541-546
31. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45
32. Knight JA, Anderson S, Rawle JM. Chemical basis of the sulfo-phospho-vanillin reaction for estimating total serum lipids. Clin Chem 1972;18:199-202
33. Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol 1959;37:911-917
34. Nguyen MT, Favelyukis S, Nguyen AK, et al. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 2007; 282:35279-35292
35. Konrad D, Wueest S. The gut-adipose-liver axis in the metabolic syndrome. Physiology (Bethesda) 2014;29:304-313
36. Gao D, Nong S, Huang X, et al. The effects of palmitate on hepatic insulin resistance are mediated by NADPH oxidase 3-derived reactive oxygen species through JNK and p38MAPK pathways. J Biol Chem 2010;285:29965-29973
37. Liu HY, Collins QF, Xiong Y, et al. Prolonged treatment of primary hepato-cytes with oleate induces insulin resistance through p38 mitogen-activated protein kinase. J Biol Chem 2007;282:14205-14212
38. Senn JJ, Klover PJ, Nowak IA, et al. Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 2003;278:13740-13746
39. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 2014;510:84-91
40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005;115:1343-1351
41. Kawano Y, Cohen DE. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 2013;48:434-441
42. Summers SA. Ceramides in insulin resistance and lipotoxicity. Prog Lipid Res 2006;45:42-72
43. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998;83:847-850
44. Thörne A, Löfgren P, Hoffstedt J. Increased visceral adipocyte lipolysis- a pathogenic role in nonalcoholic fatty liver disease? J Clin Endocrinol Metab 2010;95:E209-E213
45. Banke E, Rödström K, Ekelund M, et al. Superantigen activates the gp130 receptor on adipocytes resulting in altered adipocyte metabolism. Metabolism 2014;63:831-840
46. Amar J, Chabo C, Waget A, et al. Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3:559-572
47. Bervoets L, Van Hoorenbeeck K, Kortleven I, et al. Differences in gut mi-crobiota composition between obese and lean children: a cross-sectional study. Gut Pathog 2013;5:10
48. Kraakman MJ, Kammoun HL, Allen TL, et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab 2015;21:403-416
49. Park SK, Oh SY, Lee MY, Yoon S, Kim KS, Kim JW. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes 2004;53:2757-2766
50. Nielsen S, Guo Z, Johnson CM, Hensrud DD, Jensen MD. Splanchnic li-polysis in human obesity. J Clin Invest 2004;113:1582-1588
51. Frayn KN. Visceral fat and insulin resistance-causative or correlative? Br J Nutr 2000;83(Suppl. 1):S71-S77
52. O'Neill SM, Hinkle C, Chen SJ, et al. Targeting adipose tissue via systemic gene therapy. Gene Ther 2014;21:653-661
53. Uhrig-Schmidt S, Geiger M, Luippold G, et al. Gene delivery to adipose tissue using transcriptionally targeted rAAV8 vectors. PLoS One 2014;9:e116288